H.C. Wainwright lowered the firm’s price target on Allogene Therapeutics (ALLO) to $8 from $9 and keeps a Buy rating on the shares following the Q4 report.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALLO:
- Allogene Therapeutics management to meet virtually with Truist
- Allogene Therapeutics’ Earnings Call Highlights Progress
- Promising Pipeline and Upcoming Data Releases Drive Buy Rating for Allogene Therapeutics
- Allogene upgraded to Outperform from Market Perform at Citizens JMP
- Promising Developments in Allogene Therapeutics’ Cema-cel Therapy Highlighted by Phase I Data and Upcoming ALPHA3 Trial